KRAS and cancer: A different approach to treat KRAS-mutated cancer cells is by treating cells with a small bifunctional molecule, a proteolysis targeting chimeras (PROTACs), which engages the E3 ubiquitin ligase to KRAS to ubiquitinate KRAS for proteasomal degradation [106].